Aastrom Biosciences Acquires Sanofi's Cell Therapy and Regenerative Medicine Business
Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.
Aastrom Biosciences, a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported that it has entered into an agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks.
Through this acquisition, Aastrom is acquiring commercial rights to three marketed cell therapy products. These products include Carticel, an autologous chondrocyte implant currently marketed in the US for the treatment of articular cartilage defects, Epicel, a permanent skin replacement for burns greater than or equal to 30% of total body surface area, and MACI, a third-generation ACI product currently marketed in the EU. Aastrom will also acquire manufacturing and production centers located in the US and Denmark.
Sanofi acquired the CTRM business in 2011 through the acquisition of Genzyme Corporation.
Source: Aastrom Biosciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
